Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Tyra Biosciences in a research report issued on Wednesday, August 5th. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.86) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.80) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.20) EPS. Key Headlines Impacting Tyra BiosciencesHere are the key news stories impacting Tyra Biosciences this week:Positive Sentiment: HC Wainwright maintained its Buy rating and $45 price target for Tyra Biosciences. Tyra Biosciences stock informationHC Wainwright maintained its rating and $45 price target for Tyra Biosciences. Read MoreReceive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.